This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

First-in-Human Single Ascending and Multiple Dose of GLPG0259

This study has been completed.
Information provided by:
Galapagos NV Identifier:
First received: May 18, 2009
Last updated: February 17, 2012
Last verified: February 2012

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral dose of GLPG0259 compared to placebo.

Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0259 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Condition Intervention Phase
Healthy Drug: GLPG0259 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Double Blind, Placebo-controlled Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0259 in Healthy Subjects

Further study details as provided by Galapagos NV:

Primary Outcome Measures:
  • Safety and tolerability of single and multiple dosing [ Time Frame: up to 10 days postdose ]

Secondary Outcome Measures:
  • Pharmacokinetics of single and repeated doses [ Time Frame: up to 10 days postdose ]
  • Exploratory evaluation of TNF-alpha and IL6 in whole blood [ Time Frame: up to 12 hours postdose ]

Enrollment: 32
Study Start Date: March 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
single ascending doses
Drug: GLPG0259
single ascending doses, oral solution
Placebo Comparator: 2
single dose placebo
Drug: placebo
single dose, oral solution
Experimental: 3
multiple dose, 5 days, oral solution
Drug: GLPG0259
multiple dose, oral solution, 5 days
Placebo Comparator: 4
multiple dose, 5 days, oral solution
Drug: placebo
oral solution, 5 days


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy male, age 18-50 years
  • BMI between 18-30 kg/m², inclusive.

Exclusion Criteria:

  • significantly abnormal platelet function or coagulopathy
  • smoking
  • drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00905138

SGS Stuivenberg
Antwerp, Belgium
Sponsors and Collaborators
Galapagos NV
Study Director: Johan Beetens, PharmD, PhD Galapagos NV
Principal Investigator: Eva Vets, MD SGS Stuivenberg
  More Information

Responsible Party: Senior Vice President Development, Galapagos NV Identifier: NCT00905138     History of Changes
Other Study ID Numbers: GLPG0259-CL-101
Study First Received: May 18, 2009
Last Updated: February 17, 2012

Keywords provided by Galapagos NV:

Additional relevant MeSH terms:
Pharmaceutical Solutions processed this record on July 21, 2017